To test or not to test this should be patient’s decision – Advocates for Universal DPD/DPYD Testing

Advocates for Universal DPD/DPYD Testing shared a post by Ken Surprenanton, Advocate at DPD/DPYD, on LinkedIn, adding:

”To test or not to test: this should be PATIENT’S decision, not the doctor’s. In 2024, with the scientific knowledge of pharmacogenomics like the FDA Table of Pharmacogenomic Associations (as just one of many examples) who would want to be treated with fluoropyrimidine chemotherapy without a DPYD test? Informed patients would choose to be tested.”

Quoting Ken Surprenant’s post:

”A desperate defense of the status quo in the use of fluoropyrimidines. We, our ‘interest group’ will respond and point out that it is ultimately the patient who should decide to opt out, not the oncologist.”

Source: Advocates for Universal DPD/DPYD Testing/LinkedIn and Ken Surprenant/LinkedIn